IMA
SPRY icon

Investment Management Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Investment Management Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Buy
373,491
+14,417
+4% +$124K 0.61% 24
2026
Q1 		$2.88M Buy
359,074
+47,571
+15% +$456K 0.69% 22
2025
Q4 		$3.63M Buy
+311,503
New +$3.03M 1% 20

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Investment Management Associates's SPRY Position: Q2 2026 in Review

Investment Management Associates increased its ARS Pharmaceuticals (SPRY) stake by 4% in Q2 2026, buying an estimated $124K and bringing the position to 373,491 shares worth $2.99M. The position accounts for 0.61% of the portfolio, ranked #24.

Investment Management Associates first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.63M in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Investment Management Associates held 373,491 shares of ARS Pharmaceuticals worth $2.99M as of Q2 2026.
  • Investment Management Associates bought 14,417 ARS Pharmaceuticals shares in Q2 2026, an estimated $124K.
  • ARS Pharmaceuticals made up 0.61% of Investment Management Associates's portfolio in Q2 2026, its #24 holding.
  • Investment Management Associates first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Investment Management Associates's ARS Pharmaceuticals position peaked at $3.63M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Investment Management Associates's 13F filing for Q2 2026, filed 3 Aug 2026.